CTRI/2020/08/027106已完成未知
A PROSPECTIVE,RANDOMIZED, DOUBLE BLIND, PARALLEL DESIGN, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF VIRACIDE IN THE MANAGEMENT OF CORONA VIRUS DISEASE (COVID19)
atural Supplemets LLC0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.50 years or older
- •2.Both male and female subjects will be included
- •3.Positive oropharyngeal/nasal swab RT-PCR for Sars-Co-V2. Diagnosed not more than 2 days ago (diagnosis <=2days).
- •4.Either asymptomatic or have mild symptoms. Onset of symptoms within no more than 4 days If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more than 22 / min, resting SpO2 >95%, normal highly sensitive C-reactive protein (HS-CRP) ( <10mg/L). There are no signs of dehydration, sepsis or shortness of breath.
- •5.Chronic stable medical conditions: diabetes mellitus, or hypertension, or chronic heart disease. Under treatment and controlled by medication
- •6.Signed informed consent/or consent given through text message, WhatsApp or e-mail.
- •7.Ability to understand the requirements of the Research Protocol and follow the research procedures.
- •8.Subject should be willing to be managed in isolation wards
- •9.Negative pregnancy test (for female participants)
- •10.Adequate contraception for study duration
排除标准
- •1.Less than 50 years
- •2.With severe COVID-19 symptoms requiring immediate hospitalization
- •3.Investigator considers the subject unsuitable for ViraCide
- •4.History of symptoms of more than 4 days
- •5.COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2
- •6.History of cardiopulmonary resuscitation
- •7.Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate
- •8.Respiratory failure, ARDS or need of mechanical ventilation
- •9.History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate
- •10.History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure
- •11.History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate.
- •12.History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR.
- •13.HIV, HBsAg, HCV positive
- •14.Any condition causing immunodeficiency
- •15.Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels
- •16.History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it
- •17.History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ)
- •18.Hypersensitivity reaction to Study drug/placebo
- •19.Any psychiatric issue for which the subject is currently undergoing treatment
- •20.Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence
- •21.Inability to understand the requirements of the Research Protocol and follow the research procedures.
- •22.Pregnant or lactating;
- •23.Not willing to use adequate contraception during study duration
- •24.Participation in any other clinical study less than 3 months before the start of the study.
研究者
相似试验
已完成
不适用
A CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF Oâ??LIVER -T IN PATIENTS WITH HEPATITIS A VIRUS.CTRI/2015/01/005395SBL PVT LTD100
已完成
不适用
A CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEGETABLE POWDER IN THE MANAGEMENT OF CARDIOVASCULAR RISK FACTORS.CTRI/2016/05/006977ITC Limited288
进行中（未招募）
不适用
A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURESPatients with newly diagnosed partial seizures (with or without secondary generalization)MedDRA version: 8.1Level: LLTClassification code 10061334EpilepsyEUCTR2005-004023-19-LVPfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom800
进行中（未招募）
1 期
A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES - N/AEpilepsyEUCTR2005-004023-19-GBPfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom660
进行中（未招募）
不适用
A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES - N/AEpilepsyEUCTR2005-004023-19-CZPfizer Limited626